• 대한영상의학회지
• /
• 제81권6호
• /
• pp.1424-1435
• /
• 2020

목적 간세포암종과 혼합성 간세포암종-담관암종의 다위상 전산단층촬영술 소견과 ¹⁸F-fluorodeoxyglucose 양전자방출단층촬영(이하 FDG PET/CT)에서 섭취율 차이를 연구하여 이들의 감별 진단에 유용성이 있는지를 알아보고자 하였다. 대상과 방법 2007년 1월에서 2016년 4월까지 조직학적으로 간세포성 암종으로 진단된 84명과 혼합성 간세포암종-담관암종으로 진단된 9명의 환자를 대상으로 하였다. 조영증강 양상은 유형 I (동맥기 조영증강과 지연기 조영유실), 유형 II (지연기 조영유실이 없는 동맥기 조영증강), 유형 III (저혈관성 병변, 침투성 양상 혹은 변연부 조영증강)로 구분하였고, PET/CT 소견은 FDG 섭취 여부에 따라서 양성과 음성으로 분류하였다. 결과 혼합성 간세포암종-담관암종(89%)은 간세포암종(61%)보다 PET/CT 섭취 양성률이 높았으나 통계적으로 유의한 차이는 보이지 않았다(p = 0.095). 유형 I 조영증강양상을 보이는 58개의 간세포암종 중 37예(64%)가 PET/CT에서 양성이었다. 유형 II 조영증강양상을 보이는 19예 중 간세포암종 3예(21%)에서 PET/CT에서 양성을 보였고 혼합 간세포암종-담관암종 4예(80%)에서 PET/CT 양성을 보였다. 유형 II 조영증강양상을 보이는 경우 혼합 간세포암-담관암종이 간세포암종보다 PET/CT 양성률이 유의하게 높았다(p = 0.020). 유형 III 조영증강 양상을 보이는 16예 중 간세포암 11예(91.6%), 혼합 간세포암-담관암종 4예(100%)에서 PET/CT 양성을 보였다. 유형 III 조영증강양상을 보이는 경우 간세포암과 혼합 간세포암-담관암종의 PET/CT 양성률의 유의한 차이는 보이지 않았다. 결론 유형 II 조영증강 양상을 보이는 경우 간세포암종과 혼합성 간세포암종-담관암종의 감별진단에 전산단층촬영술과 병행하는 ¹⁸F-FDG PET/CT가 도움이 될 것으로 보인다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권11호
• /
• pp.4805-4811
• /
• 2016

Background: Hepatocellular carcinomas (HCCs) less than 2 cm in diameter generally demonstrate a good outcome after curative therapy. However, the diagnosis of small HCC can be problematic and requires one or more dynamic imaging modalities. This study aimed to compare the sensitivity and agreement between CT and MRI for the diagnosis of small HCCs. Methods: CT and/or MRI scans of HCCs (1-2 cm) diagnosed by histopathology or typical vascular pattern according to the 2005 AASLD criteria were blindly reviewed by an abdominal radiologist. The reports were defined as conclusive/typical when arterial enhancement and washout during the portal/delayed phases were observed and as inconclusive when typical vascular patterns were not observed. The sensitivity and Cohen's kappa (k) for agreement were calculated. Results: In 27 patients, 27 HCC nodules (1-2 cm) were included. Diagnosis with a single-imaging modality (CT or MRI) was 81 % versus 48 % (p = 0.01). The CT sensitivity was significantly higher than MRI (78 % versus 52 %, p = 0.04). Among 27 nodules that underwent both CT and MRI, a discordance in typical enhancement patterns was found (k = 0.319, p = 0.05). In cases with inconclusive CT results, MRI gave only an additional 3.7 % sensitivity to reach a diagnosis. In contrast, further CT imaging following inconclusive MRI results gave an additional 29.6 % sensitivity.Conclusions: A single typical imaging modality is sufficient to diagnose small HCCs. Compared with MRI, multiphasic CT has a higher sensitivity. The limitations of MRI could be explained by the greater need for patient cooperation and the types of MRI contrast agent.

• 대한영상의학회지
• /
• 제84권1호
• /
• pp.170-184
• /
• 2023

목적 Twin beam dual-energy CT (이하 tbDECT)와 dual source DECT (이하 dsDECT)를 통해 얻은 true non-contrast image (이하 TNC)와 virtual non-contrast image (이하 VNC)의 attenuation values 차이를 평가해 보고자 한다. 대상과 방법 간 DECT를 촬영한 62명의 환자를 대상으로 하였다(tbDECT, 32명; dsDECT, 30명). TNC와 재구성한 arterial VNC (이하 AVNC), portal VNC (이하 PVNC), delayed VNC (이하 DVNC)에서 복부내 11개 장기에 대해 attenuation values를 측정하여 비교하였다. 또한 TNC와 VNC attenuation values의 절대오차가 10 Hounsfield units (이하 HU) 이하인 비율을 구하였다. 결과 TNC와 VNC의 평균 attenuation values 비교에서 각 DECT별 33개의 항목(3시기 VNC, 11개 장기) 중 tbDECT는 17개, dsDECT 19개 항목에서 유의한 차이를 보였다(Bonferroni correction p < 0.0167). 절대오차 10 HU이하인 비율은 tbDECT의 AVNC, PVNC, DVNC에서 각각 56.7%, 69.2%, 78.6%, dsDECT는 각각 70.5%, 78%, 78%이었고, 두 DECT모두 AVNC에서 가장 낮았다. 결론 두 DECT의 VNC는 적지 않은 attenuation values 차이로 TNC를 대체하기에는 충분하지 않다.

• Korean Journal of Radiology
• /
• 제22권11호
• /
• pp.1909-1917
• /
• 2021

Objective: Muscle quantity and quality can be measured with an automated system on CT. However, the effects of contrast phases on the muscle measurements have not been established, which we aimed to investigate in this study. Materials and Methods: Muscle quantity was measured according to the skeletal muscle area (SMA) measured by a convolutional neural network-based automated system at the L3 level in 89 subjects undergoing multiphasic abdominal CT comprising unenhanced phase, arterial phase, portal venous phase (PVP), or delayed phase imaging. Muscle quality was analyzed using the mean muscle density and the muscle quality map, which comprises normal and low-attenuation muscle areas (NAMA and LAMA, respectively) based on the muscle attenuation threshold. The SMA, mean muscle density, NAMA, and LAMA were compared between PVP and other phases using paired t tests. Bland-Altman analysis was used to evaluate the inter-phase variability between PVP and other phases. Based on the cutoffs for low muscle quantity and quality, the counts of individuals who scored lower than the cutoff values were compared between PVP and other phases. Results: All indices showed significant differences between PVP and other phases (p < 0.001 for all). The SMA, mean muscle density, and NAMA increased during the later phases, whereas LAMA decreased during the later phases. Bland-Altman analysis showed that the mean differences between PVP and other phases ranged -2.1 to 0.3 cm² for SMA, -12.0 to 2.6 cm² for NAMA, and -2.2 to 9.9 cm² for LAMA.The number of patients who were categorized as low muscle quantity did not significant differ between PVP and other phases (p ≥ 0.5), whereas the number of patients with low muscle quality significantly differed (p ≤ 0.002). Conclusion: SMA was less affected by the contrast phases. However, the muscle quality measurements changed with the contrast phases to greater extents and would require a standardization of the contrast phase for reliable measurement.

• 대한영상의학회지
• /
• 제83권4호
• /
• pp.808-829
• /
• 2022

간세포암종은 역동적 조영증강 컴퓨터단층촬영이나 자기공명영상에서의 동맥기 조영증강 및 문맥기 또는 지연기 씻김현상과 같은 전형적 영상 소견을 기반으로 비침습적으로 진단할 수 있다. 그러나 일부 간세포암종은 비전형적인 영상 소견을 나타내기 때문에 영상의학과 의사는 진단에 있어 어려움에 직면하게 된다. 더욱이 동맥 문맥 단락, 혼합 간세포-담관암, 간내 담관암, 혈관종과 같이 많은 간세포암 유사 병변들이 다수 존재하여 영상을 통한 감별 진단에 난항을 겪는다. 초기 영상 검사에서 간세포암종과 이러한 유사 종양을 구별하는 능력은 적절한 관리 및 치료 결정에 중요하다. 따라서 본 임상화보에서는 간세포암종의 비전형적 영상 소견과 간세포암종을 모방하는 악성 및 양성 병변들의 영상 소견을 제시하고 감별 진단을 좁히는 데 도움이 될 수 있는 중요한 단서들에 대해 알아보고자 한다.

• 대한영상의학회지
• /
• 제84권6호
• /
• pp.1266-1289
• /
• 2023

악성 림프종은 역동적 조영증강 컴퓨터단층촬영에서 전형적으로 커진 림프절 이 균일한 조영증강을 보이며 내부에 괴사 및 낭성 병변을 보이지 않는 영상 소견을 보이며, 이를 통해 침습적인 진단 검사 없이도 의심할 수 있다. 그러나 일부 림프종은 비전형적인 영상 소견을 보여 영상의학과 의사가 진단하는데 어려움을 겪는다. 더욱이, 실제 임상 현장에서는 백혈병, 면역저하자의 바이러스 감염, 원발암 및 전이암들이 림프종과 유사하게 보여 감별진단하는데 어려움이 있다. 초기에 영상검사로 악성 림프종과 이러한 유사질환을 구별하는것은 적절한 치료방침을 결정하는데 중요하다. 따라서, 본 임상 화보의 목표는 림프종의 전형적, 비전형적 영상 소견과 림프종을 모방하는 병변들의 영상 소견을 보여주며, 감별 진단을 좁히는데 도움이 되는 중요한 소견들을 논의하고자 한다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권9호
• /
• pp.3595-3604
• /
• 2015

Hepatocellular carcinoma (HCC) has been one of the most fatal malignant tumors worldwide and its associated morbidity and mortality remain of significant concern. Based on in-depth reviews of serological diagnosis of HCC, in addition to AFP, there are other biomarkers: Lens culinaris agglutinin-reactive AFP (AFP-L3), descarboxyprothrombin (DCP), tyrosine kinase with Ig and eprdermal growth factor (EGF) homology domains 2 (TIE2)-espressing monocytes (TEMs), glypican-3 (GPC3), Golgi protein 73 (GP73), interleukin-6 (IL-6), and squamous cell carcinoma antigen (SCCA) have been proposed as biomarkers for the early detection of HCC. The diagnosis of HCC is primarily based on noninvasive standard imaging methods, such as ultrasound (US), dynamic multiphasic multidetector-row CT (MDCT) and magnetic resonance imaging (MRI). Some experts advocate gadolinium diethyl-enetriamine pentaacetic acid (Gd-EOB-DTPA) MRI and contrast-enhanced US as the promising imaging madalities of choice. With regard to recent advancements in tissue markers, many cuting-edge technologies using genome-wide DNA microarrays, qRT-PCR, and proteomic and inmunostaining studies have been implemented in an attempt to identify markers for early diagnosis of HCC. Only less than half of HCC patients at initial diagnosis are at an early stage treatable with curative options: local ablation, surgical resection, or liver transplant. Transarterial chemoembolization (TACE) is considered the standard of care with palliation for intermediate stage HCC. Recent innovative procedures using drug-eluting-beads and radioembolization using Yttrium-90 may exhibit beneficial effects in HCC treatment. During the past few years, several molecular targeted agents have been evaluated in clinical trials in advanced HCC. Sorafenib is currently the only approved systemic treatment for HCC. It has been approved for the therapy of asymptomatic HCC patients with well-preserved liver function who are not candidates for potentially curative treatments, such as surgical resection or liver transplantation. In the USA, Europe and particularly Japan, hepatitis C virus (HCV) related HCC accounts for most liver cancer, as compared with Asia-Pacific regions, where hepatitis B virus (HBV) may play a more important role in HCC development. HBV vaccination, while a vaccine is not yet available against HCV, has been recognized as a best primary prevention method for HBV-related HCC, although in patients already infected with HBV or HCV, secondary prevention with antiviral therapy is still a reasonable strategy. In addition to HBV and HCV, attention should be paid to other relevant HCC risk factors, including nonalcoholic fatty liver disease due to obesity and diabetes, heavy alcohol consumption, and prolonged aflatoxin exposure. Interestingly, coffee and vitamin K2 have been proven to provide protective effects against HCC. Regarding tertiary prevention of HCC recurrence after surgical resection, addition of antiviral treatment has proven to be a rational strategy.